RxDoctor Payments Data

Carlos del Rio, MD

Internal Medicine · Dracut, MANPI 1285608398

Payments from drug & device makers

$3,739in general payments, 2019–2025

Across 201 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$534
  • AstraZeneca$452
  • AbbVie$404
  • Astellas Pharma US Inc$306
  • Johnson & Johnson$233
  • Boehringer Ingelheim$221
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,53094%
  • Education$2096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,739 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$136,768
Medicare patients
334
Services billed
1,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$88,365
JardianceEmpagliflozin54$65,114
TrulicityDulaglutide28$50,631
XareltoRivaroxaban30$33,078
LinzessLinaclotide26$24,314
OzempicSemaglutide21$22,835
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$21,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$21,830
JanuviaSitagliptin Phosphate12$15,259
MounjaroTirzepatide12$12,429
OxycontinOxycodone Hcl15$11,672
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$8,478
Morphine Sulfate ErMorphine Sulfate44$7,256
SymbicortBudesonide/Formoterol Fumarate18$6,699
Omeprazole312$6,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$534$88,36577 claims
Boehringer IngelheimJardiance$221$65,11454 claims
Lilly USA, LLCTrulicity, Mounjaro$200$63,06040 claims
Johnson & JohnsonXarelto$233$33,07830 claims
AstraZenecaBreztri Aerosphere, Symbicort$452$28,67432 claims
AbbVieLinzess$404$24,31426 claims
Novo NordiskOzempic$110$22,83521 claims
GSKTrelegy Ellipta$145$21,83015 claims
MerckJanuvia$100$15,25912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Dracut

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →